PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Antibodies that are produced following infection due to the SARS-CoV-2 virus or vaccination are critical for monitoring the immune response of an individual or the impact of the vaccine over time. As vaccines become available, there is a need for rapid, accurate, and low-cost point-of-care tools for monitoring the effectiveness of the vaccines over time at the population level. Here, we report the efficiency of a handheld point-of-care thermo-photonic device for quantifying anti-SARS-CoV-2 antibodies in humanized control positive solution. Results showed that the imager in conjunction with rapid diagnostic tests (RDT) can detect and quantify antibody levels within clinically relevant range and with a limit of detection of 0.1 µg/ml.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Damber Thapa, Nakisa Samadi, Nima Tabatabaei, "Handheld Point-of-Care Device for the Quantification of Anti-SARS-CoV-2 Antibodies," Proc. SPIE PC11968, Optical Diagnostics and Sensing XXII: Toward Point-of-Care Diagnostics, PC1196803 (12 May 2022); https://doi.org/10.1117/12.2607778